{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:21:05Z","timestamp":1790673665926,"version":"4.1.0"},"reference-count":34,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2016,1,15]],"date-time":"2016-01-15T00:00:00Z","timestamp":1452816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2016,2]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Ibrutinib, an inhibitor of Bruton's tyrosine kinase, is used in the treatment of mantle cell lymphoma or chronic lymphocytic leukaemia. Ibrutinib undergoes extensive rapid oxidative metabolism mediated by cytochrome P450 3A both at the level of first pass and clearance, which might result in low oral bioavailability. The present study was designed to investigate the absolute bioavailability (F) of ibrutinib in the fasting and fed state and assess the effect of grapefruit juice (GFJ) on the systemic exposure of ibrutinib in order to determine the fraction escaping the gut (F<jats:sub>g<\/jats:sub>) and the fraction escaping hepatic extraction (F<jats:sub>h<\/jats:sub>) in the fed state.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>All participants received treatment A [560\u00a0mg oral ibrutinib, under fasting conditions], B (560\u00a0mg PO ibrutinib, fed, administered after drinking glucose drink) and C (140\u00a0mg oral ibrutinib, fed, with intake of GFJ before dosing). A single intravenous (i.v.) dose of 100\u00a0\u03bcg<jats:sup>13<\/jats:sup>C<jats:sub>6<\/jats:sub>\u2010ibrutinib was administered 2\u00a0h after each oral dose.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The estimated \u2018F\u2019 for treatments A, B and C was 3.9%, 8.4% and 15.9%, respectively. F<jats:sub>g<\/jats:sub>and F<jats:sub>h<\/jats:sub>in the fed state were 47.0% and 15.9%, respectively. Adverse events were mild to moderate in severity (Grade 1\u20132) and resolved without sequelae by the end of the study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The absolute oral bioavailability of ibrutinib was low, ranging from 3.9% in the fasting state to 8.4% when administered 30\u00a0min before a standard breakfast without GFJ and 15.9% with GFJ. Ibrutinib was well tolerated following a single oral and i.v. dose, under both fasted and fed conditions and regardless of GFJ intake status.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.12787","type":"journal-article","created":{"date-parts":[[2015,9,18]],"date-time":"2015-09-18T15:31:37Z","timestamp":1442590297000},"page":"235-245","source":"Crossref","is-referenced-by-count":65,"title":["Stable isotope\u2010labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults"],"prefix":"10.1111","volume":"81","author":[{"given":"Ronald","family":"de Vries","sequence":"first","affiliation":[{"name":"Janssen Research &amp; Development Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan W.","family":"Smit","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hellemans","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Jiao","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development Raritan NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Murphy","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development Raritan NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Skee","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development Raritan NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Snoeys","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juthamas","family":"Sukbuntherng","sequence":"additional","affiliation":[{"name":"Pharmacyclics, Inc. Sunnyvale CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Vliegen","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loeckie","family":"de Zwart","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Mannaert","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"de Jong","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,1,15]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2011.1.110"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2013.1.158"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-013-0188-8"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation.V2012.1.88.3801172"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-515361"},{"key":"e_1_2_9_7_1","unstructured":"IMBRUVICA\u00aeprescribing information. Pharmacyclics Inc. RevisedJuly2014."},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.7906"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70335-3"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"e_1_2_9_12_1","doi-asserted-by":"crossref","unstructured":"deJongJ SkeeD MurphyJ SukbuntherngJ HellemansP SmitJ deVriesR JiaoJ. Effect of CYP3A perpetrators on ibrutinib exposure in normal healthy subjects. Pharma Res Per2015;3: e00156.","DOI":"10.1002\/prp2.156"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.114.060061"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-015-2708-9"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.3109\/03639045.2011.571697"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2012.04.005"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(03)00118-8"},{"key":"e_1_2_9_18_1","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S0090-9556(24)15346-9","article-title":"Role of furanocoumarin derivatives on grapefruit juice\u2010mediated inhibition of human CYP3A activity","volume":"28","author":"Guo LQ","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00192360"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/83.5.1097"},{"key":"e_1_2_9_21_1","first-page":"1228","article-title":"Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism\u2010based inactivation by furanocoumarins","volume":"25","author":"Schmiedlin\u2010Ren P","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_9_22_1","first-page":"461","article-title":"Grapefruit juice interaction with oral budesonide: equal effect on immediate\u2010release and delayed\u2010release formulations","volume":"64","author":"Seidegard J","year":"2009","journal-title":"Pharmazie"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.104215"},{"key":"e_1_2_9_24_1","unstructured":"ICH\u2010M3. ICH Topic M3 (R2). Non\u2010clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. International Conference on Harmonization of technical Requirements for Registration of Pharmacueticals for Human Use2009."},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04391.x"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1021\/ac300442v"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1021\/ac3024558"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2011.553189"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2621.2005.tb07178.x"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(00)00104-3"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.18.365"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1053\/cp.1999.v66.a101208"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270003256059"},{"key":"e_1_2_9_34_1","unstructured":"Guidance to the conduct of exploratory (phase 0) trials inBelgium(FAGG version 2 January2012) [online]. Available athttp:\/\/www.fagg\u2010afmps.be(last accessed 24June2015)."},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-014-2617-3"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.12787","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.12787","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T18:15:17Z","timestamp":1748628917000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.12787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,15]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["10.1111\/bcp.12787"],"URL":"https:\/\/doi.org\/10.1111\/bcp.12787","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,15]]}}}